BD Receives FDA 510(k) Clearance on BD Phoenix Meropenem-Vaborbactam Panel

4 Jul 2018
Aidan Barry
Administrator / Office Personnel

BD introduces the ability to execute in vitro rapid identification (ID) and antimicrobial susceptibility testing (AST) for meropenem-vaborbactam in a new panel for the BD Phoenix™ Automated Microbiology System, which detects resistance in Enterobacteriaceae, Non-Enterobacteriaceae and most gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus.

The BD Phoenix™ offers clinical microbiology laboratories the ability to rapidly and accurately test antimicrobial resistances or susceptibilities. BD’s rapid and reliable results for ID and AST are powered through an oxidation-reduction indicator with turbidity measurement for growth detection, as well as full on-panel antimicrobial concentrations and the BDXpert system for data analysis.

For more products from BD Diagnostics, visit the SelectScience product directory >>>>

Links

Tags